163 related articles for article (PubMed ID: 24169177)
1. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis.
Hernandez JM; Tsalatsanis A; Humphries LA; Miladinovic B; Djulbegovic B; Velanovich V
Ann Surg; 2014 Jun; 259(6):1208-14. PubMed ID: 24169177
[TBL] [Abstract][Full Text] [Related]
2. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.
Cucchetti A; Djulbegovic B; Tsalatsanis A; Vitale A; Hozo I; Piscaglia F; Cescon M; Ercolani G; Tuci F; Cillo U; Pinna AD
Hepatology; 2015 Mar; 61(3):905-14. PubMed ID: 25048515
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma.
Lee SR; Kim HO; Son BH; Yoo CH; Shin JH
Hepatogastroenterology; 2013; 60(122):358-62. PubMed ID: 23574658
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement.
Abbott DE; Merkow RP; Cantor SB; Fleming JB; Varadhachary GR; Crane C; Bentrem DJ; Bilimoria KY
Ann Surg Oncol; 2012 Nov; 19(12):3659-67. PubMed ID: 22965567
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors.
Cleary SP; Gryfe R; Guindi M; Greig P; Smith L; Mackenzie R; Strasberg S; Hanna S; Taylor B; Langer B; Gallinger S
J Am Coll Surg; 2004 May; 198(5):722-31. PubMed ID: 15110805
[TBL] [Abstract][Full Text] [Related]
7. A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making.
Tsalatsanis A; Hozo I; Vickers A; Djulbegovic B
BMC Med Inform Decis Mak; 2010 Sep; 10():51. PubMed ID: 20846413
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.
Gobbi PG; Bergonzi M; Comelli M; Villano L; Pozzoli D; Vanoli A; Dionigi P
Cancer Epidemiol; 2013 Apr; 37(2):186-90. PubMed ID: 23369450
[TBL] [Abstract][Full Text] [Related]
10. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
[TBL] [Abstract][Full Text] [Related]
11. Significance of pathologic response to preoperative therapy in pancreatic cancer.
Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
Dabaja BS; Suki D; Pro B; Bonnen M; Ajani J
Cancer; 2004 Aug; 101(3):518-26. PubMed ID: 15274064
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis of veteran patients with pancreatic cancer.
Kim D; Zhu H; Nassri A; Mokdad A; Kukreja S; Polanco P; Huerta S; Ramzan Z
J Dig Dis; 2016 Jun; 17(6):399-407. PubMed ID: 27235863
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.
Müller MW; Friess H; Köninger J; Martin D; Wente MN; Hinz U; Ceyhan GO; Blaha P; Kleeff J; Büchler MW
Am J Surg; 2008 Feb; 195(2):221-8. PubMed ID: 18154768
[TBL] [Abstract][Full Text] [Related]
15. Acceptable regret in medical decision making.
Djulbegovic B; Hozo I; Schwartz A; McMasters KM
Med Hypotheses; 1999 Sep; 53(3):253-9. PubMed ID: 10580533
[TBL] [Abstract][Full Text] [Related]
16. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials.
Cubiella J; Castells A; Fondevila C; Sans M; Sabater L; Navarro S; Fernández-Cruz L
Am J Gastroenterol; 1999 May; 94(5):1271-8. PubMed ID: 10235206
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
[TBL] [Abstract][Full Text] [Related]
19. Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.
Stalmeier PF; van Tol-Geerdink JJ; van Lin EN; Schimmel E; Huizenga H; van Daal WA; Leer JW
J Clin Oncol; 2007 Jul; 25(21):3096-100. PubMed ID: 17634489
[TBL] [Abstract][Full Text] [Related]
20. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
